Measurable residual disease (MRD) is a critical diagnostic tool that predicts disease progression and is increasingly used as an important end point to monitor disease status and evaluate novel ...

Panelists highlight that menin inhibitors represent a breakthrough in the treatment of KMT2A-rearranged AML by targeting the disease’s core epigenetic drivers, with early clinical trials like ...

Mixed phenotype acute leukemia is when these two forms of leukemia combine. If you have too few normal white blood cells, you may get infections and fevers over and over. A high white blood cell count ...

Treosulfan plus fludarabine is approved for alloHSCT in patients with AML or MDS aged 1 year and older. Clinical trial results showed improved overall survival with treosulfan compared to busulfan.

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...

Acute myeloid leukemia (AML) is deadly hematologic malignancy. Despite a well-characterized genetic and molecular landscape, targeted therapies for AML have failed to significantly improve clinical ...

UK-based biotech Charm Therapeutics has closed an oversubscribed Series B funding round worth $80m, which will support the progression of its acute myeloid leukaemia (AML) menin inhibitor into ...